EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. - Wikidata - awgldk - TriplyDB

EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies.

EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies.

http://www.wikidata.org/entity/Q34165364

about

Biological features and biomarkers in hepatocellular carcinoma Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets Epigenetics in liver disease: from biology to therapeutics Epigenetic regulation in hepatocellular carcinoma requires long noncoding RNAs Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients' adverse prognosis.Overexpression of ZEB2 in peritumoral liver tissue correlates with favorable survival after curative resection of hepatocellular carcinoma.MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma.A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values EZH2, a unique marker of malignancy in effusion cytology.Protein expression of ZEB2 in renal cell carcinoma and its prognostic significance in patient survival Hepatocellular carcinoma: clinical frontiers and perspectives.Leukemia inhibitory factor receptor is a novel immunomarker in distinction of well-differentiated HCC from dysplastic nodules Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors.Genetic alteration and misexpression of Polycomb group genes in hepatocellular carcinoma.Overexpression of RNF2 Is an Independent Predictor of Outcome in Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy.Global proteomic profiling in multistep hepatocarcinogenesis and identification of PARP1 as a novel molecular marker in hepatocellular carcinoma.Prognostic factors affecting postoperative survival of patients with solitary small hepatocellular carcinoma.EZH2 down-regulation exacerbates lipid accumulation and inflammation in in vitro and in vivo NAFLD.Decreased expression of PTPN12 correlates with tumor recurrence and poor survival of patients with hepatocellular carcinoma.Hepatoepigenetic Alterations in Viral and Nonviral-Induced Hepatocellular Carcinoma.Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives.Epigenetic dysregulation in hepatocellular carcinoma: focus on polycomb group proteins.DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance.Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility.Context-dependent actions of Polycomb repressors in cancer.High expression of FUNDC1 predicts poor prognostic outcomes and is a promising target to improve chemoradiotherapy effects in patients with cervical cancer.Heat shock proteins in hepatocellular carcinoma: Molecular mechanism and therapeutic potential.CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma.Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics.ACK1 promotes gastric cancer epithelial-mesenchymal transition and metastasis through AKT-POU2F1-ECD signalling.Tissue Biomarkers in Hepatocellular Tumors: Which, When, and How.EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin.Histone-modifying genes as biomarkers in hepatocellular carcinoma.Anti-cancer effects of curcumin on lung cancer through the inhibition of EZH2 and NOTCH1.Overexpression of NKX6.1 is closely associated with progressive features and predicts unfavorable prognosis in human primary hepatocellular carcinoma.Polycomb Repressor Complex 2 in Genomic Instability and Cancer Reevaluation of glypican-3 as a prognostic marker in HCC using X-tile software.Glyoxylate reductase/hydroxypyruvate reductase: a novel prognostic marker for hepatocellular carcinoma patients after curative resection.Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC.From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma.

P2860

Q26799462-218FF5B7-F0A8-488D-8E2A-1F2DF2E25234 Q27311589-8F0746A5-CED5-4137-8452-A908075DC958 Q28079271-FB03FCDF-F725-4AA0-BA0B-C4DE28C4999D Q28084553-C0F1A080-5DB9-4B9F-A617-4767D922FE7F Q34147688-302D5F9C-7BCC-41FB-8CBF-054851EDF9DC Q34186021-750E5AD1-9551-4404-A2BD-B7E0127FBE83 Q34409807-CD976C09-6009-40B7-A6EB-F98FC46C2A7A Q34640456-6A5609AC-8A5A-44C3-B294-A3D2D4FA7BF8 Q34699488-41CC8A3C-0F29-4C41-B6D4-4D4C5D4389A9 Q34712612-0755D694-F95C-4222-8614-3C64901065C6 Q35112053-CE603AC6-17D4-4760-A3E9-D1CB294C6BE2 Q35740127-8766AEEA-07E4-4C96-9E38-E0EE0CCE34E2 Q36217858-917877B8-E738-4244-BF38-6356C4277101 Q36309367-B2AA055F-08CE-4AB8-83AD-AFE536CB8A54 Q36574137-A931966C-96F3-43E1-922D-40D7EE7D8B73 Q37046449-65541A9D-1533-4204-A0E8-D44C720AF183 Q37178647-2DCE2CBB-AEE2-48E3-9B0B-A22019D42640 Q37420964-BB7BCE06-CD62-4924-9F46-BDD30BE741ED Q37514154-FE12D2C8-2E9B-4F6F-BC04-37A10D2622CF Q37571496-A5911F5B-61AB-439A-8092-E08BB026AC6E Q37581334-4995B5A9-0FCC-477D-A1FF-E10A168EB299 Q38101901-37FC890E-1B41-414D-8254-9CED6AE994B0 Q38238954-D7363B94-111E-46E9-BD36-D19AFD5A1530 Q38450711-9C1BD9DA-909E-42F1-A1E9-47CF7C6AAF85 Q38518851-9C1BA772-9952-4C40-902C-989F8EC880B0 Q38673989-0340F729-1D5B-4543-B5E9-F54804626D47 Q38725577-7DABD741-F9AD-486C-89B8-A5FCFFBA8817 Q38769532-CA862FAF-EA8F-4652-A271-FFB1DC6C53AB Q38857804-BEE4888A-048D-42A9-9E2D-DAD5C7B830E8 Q38910111-7EA6D299-1263-4248-B741-D1ED245FE444 Q39172203-A2EAF7E5-AB96-44E3-95EF-DCD6FF023F17 Q39521859-6F34996C-0900-4BFA-A8D0-24D8995F8536 Q41135024-E0F1DC40-1FCE-4700-AF37-AF0724B9F66C Q41225460-3BC2C249-0BE6-4D14-BDCD-B99E755F6F08 Q41570382-230D1368-5B67-4DF0-A964-F613A9CC9135 Q41573279-D52FC6ED-E6BF-43AC-BD9A-CB5468FDF15D Q41644454-64DC9CA0-F020-477D-901F-0408BA66FF02 Q45384144-34AC61D4-1CF0-4F03-8506-7387CBEBB638 Q47547759-B1618F07-94D3-4235-9438-FE5CCBD3C5F8 Q47842185-E6B72D55-CA0D-4F40-B77C-145903ECA04F

P2860

EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies.

http://www.wikidata.org/entity/Q34165364

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

EZH2 protein: a promising immu ...... omas in liver needle biopsies.

@ast

EZH2 protein: a promising immu ...... omas in liver needle biopsies.

@en

EZH2 protein: a promising immu ...... omas in liver needle biopsies.

@nl

type

label

EZH2 protein: a promising immu ...... omas in liver needle biopsies.

@ast

EZH2 protein: a promising immu ...... omas in liver needle biopsies.

@en

EZH2 protein: a promising immu ...... omas in liver needle biopsies.

@nl

prefLabel

EZH2 protein: a promising immu ...... omas in liver needle biopsies.

@ast

EZH2 protein: a promising immu ...... omas in liver needle biopsies.

@en

EZH2 protein: a promising immu ...... omas in liver needle biopsies.

@nl

P1433

Q34165364-9FB07DA2-F6DF-400C-8271-DCAFC46BF3F6

P1476

Q34165364-40D12E85-F309-4813-A56F-69DEC66126F2

P2093

Q34165364-0434843A-2045-4E2D-8EB6-2462897939BA

Q34165364-5EE8D946-377B-48B9-A601-BC750729F2B3

Q34165364-691E4358-2CD5-4140-98E2-5DAF797F0519

Q34165364-6A1F72EE-2229-4437-9B63-3C62353D52F1

Q34165364-91C25DCF-A4F0-44A6-A1FB-AEB0E1A775D8

Q34165364-91E4E902-D52B-4BBF-A4F8-E5C5AB83F76F

Q34165364-96ED1DB7-DE42-4763-96D8-6DC0622932D6

Q34165364-9AD14103-BE30-41C4-91C1-FB4F5CF4A2BC

Q34165364-CCC56368-D461-4BDC-9BB3-D7EBF5E51E08

Q34165364-DAD2EBB1-C6AB-4F63-BCE5-8E95EE45248F

P304

Q34165364-3CE07F29-908A-4F6E-9F36-7BD26680362C

P31

Q34165364-E8879ADE-C0E9-4B24-8664-9D1B5A7A9673

P356

Q34165364-05997A4A-97C5-4FE5-A830-164C890D90C2

P407

Q34165364-10BC8746-60C0-4A26-A4C0-305EFE5BB0A0

P433

Q34165364-6FBFAB60-7C1C-442C-91EC-2A34E4B26343

P478

Q34165364-544B5292-FB96-4ABB-A32C-CC02FE4E3A9A

P577

Q34165364-212134FA-ECBF-418C-B4EF-13545F7C98A4

P5875

Q34165364-6C17C47C-1293-493E-9FD4-F595E1B1238B

P698

Q34165364-B3F642FD-61A4-4532-9BAD-1350E4FE05D4

P356

GUT.2010.231993

P1433

P1476

EZH2 protein: a promising immu ...... omas in liver needle biopsies.

@en

P2093

Dan Xie

http://www.w3.org/2001/XMLSchema#string

Fang Zheng

http://www.w3.org/2001/XMLSchema#string

Hsiang-Fu Kung

http://www.w3.org/2001/XMLSchema#string

Hui-Lan Rao

http://www.w3.org/2001/XMLSchema#string

Marie C Lin

http://www.w3.org/2001/XMLSchema#string

Mu-Yan Cai

http://www.w3.org/2001/XMLSchema#string

Qiu-Liang Wu

http://www.w3.org/2001/XMLSchema#string

Xin-Yuan Guan

http://www.w3.org/2001/XMLSchema#string

Yan-Hui Liu

http://www.w3.org/2001/XMLSchema#string

Yang-Chao Chen

http://www.w3.org/2001/XMLSchema#string

P304

967-976

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.2010.231993

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49844965

http://www.w3.org/2001/XMLSchema#string

P698

21330577

http://www.w3.org/2001/XMLSchema#string